Orchid Pharma Ltd Share Price Today - Orchid Pharma Ltd Stock Price Live NSE/BSE

Orchid Pharma Ltd

NSE: ORCHPHARMA BSE: 524372

₹691.95

(1.68)%

Mon, 09 Feb 2026, 04:44 am

MTF 5xInvest in Orchid Pharma Ltd with 5x Leverage Buy with MTF

Market Cap34.55B

PE Ratio67.16

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

1 Day

0 (0%)

No Result Found

Summary

Market Cap
3455.24
Net Profit
95.76
P/B
3.29
Sector P/E
31.99
P/E
39.54
EV/EBITDA
27.13
Debt/Equity (Industry)
0.22
Interest Cover (Industry)
10.71
ROCE (Industry)
11.89
RONW (Industry)
11.62
ROE
2.86
ROCE
3.15
Debt/Equity
0.13
EPS (TTM)
10.30
Dividend Yield
0
Book Value
251.16
Interest Cover
7.40

Analysis

No Result Found

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	69.84	69.84	69.84	69.84	69.84
FII	1.17	1.56	1.40	2.69	2.53
DII	19.39	19.04	19.43	20.10	18.99
Public	9.60	9.57	9.34	7.38	8.64
Government	0	0	0	0	0

Technical Analysis

RSI

41.28

MACD

-20.81

50 DMA

764.15

200 DMA

752.06

Support and Resistance

Type	R1	R2	R3	PP	S1	S2	S3
Classic	991.37	858.37	778.73	725.37	645.73	592.37	459.37
Fibonacci	858.37	807.56	776.17	725.37	674.56	643.17	592.37
Camarilla	735.68	723.48	711.29	725.37	686.91	674.72	662.52

Pivots Level: Classic

+266

991.37

+133

858.37

+53.37

778.73

725.37

Pivot Point

LTP: 691.95

-79.63

645.73

-133

592.37

-266

459.37

Moving Average

SMAEMA

Period

Value

10-EMA
693.41
20-EMA
707.64
30-EMA
722.07
50-EMA
740.78
100-EMA
760.57
200-EMA
813.99

Announcement Date	Purpose	Action	Ex Date
12 Aug 2025	agm
29 May 2025	egm
17 Jul 2024	agm
08 Jul 2023	agm
02 Dec 2022	egm
22 Jun 2022	agm
22 Jul 2021	agm
05 Jun 2021	egm
05 Dec 2020	agm

Orchid Pharma Ltd

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Cipla Ltd

Dr Reddys Laboratories Ltd

About Orchid Pharma Ltd

Orchid Pharma 01 the leading ptlarrna<;eutlcal oompanies in India haad quartered In Channai and Involved in the davelopment, manufacture and marketing of diverse bulk aeWes. formulationS and nutraceu~cals with exports spanning over 40 counllies. Orcttid's world class manufacturing infrasl1uclure Include USFDA compliant API and Finished Dosage Form faciliUes at Chennai In India. OrctIid lias dediCilted stale-of-art and GLP compliant R&D infrastructure fOf Procen researetl, Drug Discovery and Pllarmaceut!cal researen at Chennal, India.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1992

Headquarters

CEO

R G Agarwal

Employees

Contact

Website

http://www.orchidpharma.com

corporate@orchidpharma.com

Phone

91-44-28211000/28230000

Location

Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road, Chennai, Tamil Nadu, 600034

Year	History
2015	The company received approval from the US FDA for the Abbreviated New Drug Application. The company changed its name from Orchid Chemicals & Pharmaceuticals Ltd to Orchid Pharma Ltd. The trading symbol of the company changed from ORCHIDCHEM to ORCHIDPHAR.
2016	Orchid received final USFDA approval for Rasagiline generic formulation.
2022	Orchid Pharma Limited launched a Qualified Institutional Placement programme of INR 500 Crore.
2023	Orchid Bio Pharma was granted approval by the Competent Authority under the Production Linked Incentive Scheme for manufacturing of product 7 ACA.
2024	The company Board of Directors informed about the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited under Regulation SEBI.

Client Name	Order Side	QTY	Avg Price	Date
UTI MUTUAL FUND	Buy	366507	615.37	30 May 2025

orchid pharma limited News

Orchid Pharma Q3FY26 Earnings Call Set for Feb 12

Orchid Pharma Limited announces analysts/investors earnings call on February 12, 2026 at 4:30 PM IST to discuss Q3FY26 financial results ended December 31, 2025, hosted by Systematix Institutional Equities.

06 Feb 2026

co actions results

Orchid Pharma Q2 FY26 Results: Revenue Declines 13% YoY to INR 194 Crores Amid Antibiotics Market Downturn

Orchid Pharma reported quarterly sales of INR 194 crores, down 13% year-on-year, with gross margins compressed to 32% from 43% due to inventory revaluation and weak antibiotic market conditions. The company completed acquisition of global rights to Enmetazobactam (Exblifep) and reported strong domestic performance with 15,000 patients treated and 200,000+ vials sold through its Orblicef brand partnership with Cipla.

17 Nov 2025

earnings

Orchid Pharma Reports Delays in QIP-Funded Projects, Revises Fund Allocation

Orchid Pharma Limited submitted its monitoring agency report for the quarter ended September 30, 2025, regarding the utilization of Rs. 400 crore raised through Qualified Institutional Placement. The company revised the allocation of QIP proceeds among project objectives following shareholder approval through AGM resolution dated September 20, 2025. Two key projects face implementation delays: the investment in Orchid BioPharma Limited for setting up manufacturing facility in Jammu, and funding capital expenditure for new API facility block in Alathur, Tamil Nadu, though the extent of delays remains unascertainable. For the Jammu project, Rs. 73.02 crores has been utilized as of September 30, 2025, with land acquisition challenges cited as the primary cause of delay. Registration of 164.50 Kanal out of 203.8 Kanal identified land has been completed, with remaining land registration expected by December 2025. The Alathur project delay is attributed to dependency on the Jammu 7ACA project, with only Rs. 0.36 crores utilized. The company has deployed unutilized proceeds in fixed deposits with Yes Bank Limited. CARE Ratings Limited served as the monitoring agency and reported no deviation from stated objectives.

13 Nov 2025

corporate action

Orchid Pharma Plans Capacity Expansion and New Product Launches with 13% Revenue Growth Target

Orchid Pharma is targeting capacity expansion and new product launches across Cephalosporin and Carbapenem APIs. The company projects FY26 revenue growth of 13% year-on-year. A new plant in Chennai is being commissioned to enhance API output by 25%. The company is focusing on export market penetration and backward integration. The R&D pipeline includes 8 new molecules. Orchid Pharma expects volume-led growth and higher EBITDA margins in FY26-27.

11 Nov 2025

stock

Orchid Pharma Reports Strong Q2 Performance with 12% Revenue Growth and Profit Turnaround

Orchid Pharma Limited announced its quarterly results for the quarter ended September 30, 2025. The company reported standalone net sales of Rs 193.52 crores compared to Rs 172.93 crores in the previous quarter, marking growth in revenue. The company achieved a standalone profit before tax of Rs 20.23 crores for the current quarter versus Rs 204.29 crores in the previous quarter. Basic earnings per share stood at Rs 0.44 for the quarter. The company completed acquisitions of 100% assets of Alectra Therapeutics GmbH, Germany and Alectra Therapeutics SAS, France, gaining global ownership of Enmetazobactam antibiotic molecule. Orchid Pharma also acquired 100% share capital of Weichensee 1272 VV GmbH, Germany, now renamed as Orchid Pharma Europe GmbH. The Board of Directors approved the unaudited financial results in a meeting held on November 11, 2025. The company has submitted a petition for amalgamation with its holding company Dhanuka Laboratories Limited to the National Company Law Tribunal, Chennai bench.

11 Nov 2025

earnings

Showing 1–5 of 30

Rows per page:

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800